Detalhe da pesquisa
1.
Adaptive responses to antibody based therapy.
Semin Cell Dev Biol
; 50: 153-63, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26808665
2.
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Mol Cancer
; 13: 242, 2014 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25344208
3.
Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol.
Mol Cancer Ther
; 17(1): 204-214, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054984
4.
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
Mol Cancer Ther
; 17(11): 2297-2308, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093568
5.
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Mol Cancer Ther
; 15(9): 2175-86, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27422810
6.
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 21(11): 2601-12, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25767293
7.
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 24(23): 6099, 2018 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510088